Malignant News and Research

RSS

Implementing population level changes could avoid up to 50% of deaths from CVD

Up to 50% of deaths from cardiovascular disease in Europe could be avoided by implementing population level changes such as taxation and regulation of advertising. Population level prevention will produce greater impacts on CVD than individualised approaches, according to the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) of the European Society of Cardiology (ESC).

24 Jul 2012

Novel genomic sequencing method can help conduct in-depth analysis of single cells

Only by viewing a Georges Seurat painting at close range can you appreciate the hidden complexities of pointillism - small, distinct dots of color applied to form an image from a distance. Similarly, biologists and geneticists have long sought to analyze profiles of genes at the single cell level but technology limitations have only allowed a view from afar.

23 Jul 2012

Researchers link specific gene mutations with four recognized subtypes of medulloblastoma

Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and several collaborating institutions have linked mutations in specific genes to each of the four recognized subtypes of medulloblastoma, the most common malignant brain tumor of children. The discovery, reported July in the journal Nature, provides doctors with potential biomarkers for guiding and individualizing treatment and reveals prospective therapeutic opportunities for countering this devastating malignancy.

23 Jul 2012

Surgeon-performed ultrasonography ‘indispensable’ for thyroid disease detection

Ultrasonography-guided fine-needle aspiration biopsy, when performed by a surgeon, offers benefits in terms of clinical accuracy in detecting thyroid disease, show Turkish study results.

19 Jul 2012

Inhibiting STAT3 might unleash an effective anti-lymphoma immune response

Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.

19 Jul 2012

NCCN Guidelines for Patients: Lung Cancer Screening now available free of charge

The National Comprehensive Cancer Network (NCCN), with the support of the NCCN Foundation and Lung Cancer Alliance, announces the latest addition to the library of NCCN Guidelines for Patients, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology.

19 Jul 2012

Estrogen may mediate low incidence of HCC in women

Study findings suggest that estrogen may have a suppressive effect on hepatocellular carcinoma, potentially explaining its lower incidence in women.

18 Jul 2012

Rheumatoid arthritis patients take-up cancer screening

Insurance records for rheumatoid arthritis patients in the USA indicate that patients are receiving their recommended cervical, breast, and colon cancer screening tests.

16 Jul 2012

Bioethicists discuss personal experiences with cancer in new book

"Since my diagnosis, I had been immersed in a crash course in real-world medical ethics," writes Rebecca Dresser, editor of Malignant: Medical Ethicists Confront Cancer, published by Oxford University Press. She and five other bioethicists discuss their personal experiences with cancer or caring for loved ones with the disease, with lessons for doctors and nurses, patients, and caregivers.

14 Jul 2012

High-risk HPV may increase chances of second malignancy in oral cancer

The proportion of oral squamous cell carcinoma patients infected with the human papillomavirus could be around a third, with high-risk versions of the virus accounting for almost three-quarters of those affected, indicate Taiwanese study results.

12 Jul 2012

US hospitals fail to meet critical esophagectomy benchmark

A study has shown that most US hospitals fail to ensure that surgeons examine at least 15 lymph nodes during esophagectomy for cancer, and are therefore failing to meet guideline recommendations for detecting metastases.

12 Jul 2012

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has established the University of California San Francisco (UCSF) as the second enrolling site for its Phase II Merkel cell carcinoma clinical trial (OMS-I110).

11 Jul 2012

Cylene's Pol I inhibitor activates p53 and selectively destroys cancer cells

Cylene Pharmaceuticals today announced that research collaborators at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia have established, for the first time, that RNA Polymerase I (Pol I) activity is essential for cancer cell survival and that its inhibition selectively activates p53 to kill tumors. Published today in Cancer Cell, the findings show that Cylene's Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant but not in normal cells.

11 Jul 2012

Genetic test helps avoid needless thyroid surgery

US researchers report that a gene-based test may help to identify patients who have cytologically indeterminate thyroid nodules that are benign.

10 Jul 2012

Sox10 gene plays a central role in melanoma

Black skin cancer, also known as melanoma, is particularly aggressive and becoming increasingly common in Switzerland. Despite intensive research, however, there is still no treatment. Researchers from the University of Zurich have now discovered a gene that plays a central role in black skin cancer. Suppressing this gene in mice inhibits the development of melanoma and its proliferation - a discovery that could pave the way for new forms of therapy.

10 Jul 2012

MammaPrint more cost-effective and clinically-useful test than Oncotype DX

New research from University of the Sciences' Mayes College of Healthcare Business and Policy suggests that MammaPrint - a gene expression profiling (GEP) test used to identify whether women with early-stage breast cancer would benefit from chemotherapy - is the more cost-effective and clinically-useful test than the most frequently used GEP in practice in the United States today.

10 Jul 2012

Blocking a fundamental process deep within cancer cells can selectively kill them

Investigators reporting in the July issue of the Cell Press journal Cancer Cell have found that blocking a fundamental process deep within cancer cells can selectively kill them and spare normal cells.

10 Jul 2012

Cook Medical receives FDA clearance for Evolution Colonic Controlled-Release Stent

The U.S. Food and Drug Administration (FDA) has granted Cook Medical 510(k) clearance for the Evolution Colonic Controlled-Release Stent, Cook announced today.

9 Jul 2012

Novel treatment for cancer based on protein from HIV-1 virus

Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.

9 Jul 2012

Bioengineers develop microfluidic platform to mechanically confine cancer cells

It's well known in conventional biology that during the process of mammalian cell division, or mitosis, a mother cell divides equally into two daughter cells. But when it comes to cancer, say UCLA researchers, mother cells may be far more prolific.

6 Jul 2012